2024

Yu, Y.-L. et al. (2024) Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart, 110(19), pp. 1180-1187. (doi: 10.1136/heartjnl-2023-323796) (PMID:38729636)

Catanese, L. et al. (2024) Differentiating primary and secondary FSGS using non-invasive urine biomarkers. Clinical Kidney Journal, 17(2), sfad296. (doi: 10.1093/ckj/sfad296) (PMID:38313685) (PMCID:PMC10833144)

2023

Mischak, H. (2023) Comment on ‘A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension’ by Lin et al. Journal of Hypertension, 41(10), p. 1666. (doi: 10.1097/HJH.0000000000003489) (PMID:37642594)

De Beer, D., Mels, C. M.C., Schutte, A. E., Delles, C. , Mary, S. , Mullen, W. , Latosinska, A., Mischak, H. and Kruger, R. (2023) Identifying a urinary peptidomics profile for hypertension in young adults: the African-PREDICT study. Proteomics, 23(11), 2200444. (doi: 10.1002/pmic.202200444) (PMID:36943111)

Degenaar, A., Jacobs, A., Kruger, R., Delles, C. , Mischak, H. and Mels, C.M.C. (2023) Cardiovascular risk and kidney function profiling using conventional and novel biomarkers in young adults: the African-PREDICT study. BMC Nephrology, 24, 96. (doi: 10.1186/s12882-023-03100-w) (PMID:37055746) (PMCID:PMC10103421)

Rotbain Curovic, V. et al. (2023) Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – a post-hoc analysis of the PRIORITY randomized clinical trial. Journal of Diabetes and its Complications, 37(4), 108433. (doi: 10.1016/j.jdiacomp.2023.108433) (PMID:36841085)

Mokou, M., Mischak, H. and Frantzi, M. (2023) Statistical determination of cancer biomarkers: moving forward clinically. Expert Review of Molecular Diagnostics, 23(3), pp. 187-189. (doi: 10.1080/14737159.2023.2187290) (PMID:36877119)

de Beer, D., Mels, C. M. C., Schutte, A. E., Delles, C. , Mary, S. , Mullen, W. , Mischak, H. and Kruger, R. (2023) A urinary peptidomics approach for early stages of cardiovascular disease risk: the African-PREDICT study. Hypertension Research, 46(2), pp. 485-494. (doi: 10.1038/s41440-022-01097-7) (PMID:36396816)

Frantzi, M. et al. (2023) Mass spectrometry-based biomarkers to detect prostate cancer: a multicentric study based on non-invasive urine collection without prior digital rectal examination. Cancers, 15(4), 1166. (doi: 10.3390/cancers15041166) (PMID:36831508) (PMCID:PMC9954607)

2022

Frantzi, M. et al. (2022) Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer. World Journal of Urology, 40(9), pp. 2195-2203. (doi: 10.1007/s00345-022-04077-1) (PMID:35841414)

O’Connell, S. P. et al. (2022) A model to detect significant prostate cancer integrating urinary peptide and extracellular vesicle RNA data. Cancers, 14(8), 1995. (doi: 10.3390/cancers14081995) (PMID:35454901) (PMCID:PMC9027643)

Wei, D. et al. (2022) The novel proteomic signature for cardiac allograft vasculopathy. ESC Heart Failure, 9(2), pp. 1216-1227. (doi: 10.1002/ehf2.13796) (PMID:35005846) (PMCID:PMC8934921)

2021

He, T. et al. (2021) Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 23(11), pp. 1875-1887. (doi: 10.1002/ejhf.2195) (PMID:33881206)

Hupe, M. C., Hempel, M. C., Rodler, S., Frantzi, M., Mischak, H., Merseburger, A. S., Stief, C. G. and Chaloupka, M. (2021) Diagnostische marker in der Urologie. Urologe, 60(10), pp. 1323-1330. (doi: 10.1007/s00120-021-01568-8) (PMID:34156515)

He, T. et al. (2021) Serum and urinary biomarkers of collagen type‐I turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 11(1), e267. (doi: 10.1002/ctm2.267) (PMID:33463057) (PMCID:PMC7803349)

2020

Mokou, M. et al. (2020) A novel pipeline for drug repurposing for bladder cancer based on patients’ omics signatures. Cancers, 12(12), 3519. (doi: 10.3390/cancers12123519) (PMID:33255925) (PMCID:PMC7759896)

Frantzi, M., Hupe, M. C., Merseburger, A. S., Schanstra, J. P., Mischak, H. and Latosinska, A. (2020) Omics derived biomarkers and novel drug targets for improved intervention in advanced prostate cancer. Diagnostics, 10(9), 658. (doi: 10.3390/diagnostics10090658) (PMID:32878288)

Latosinska, A., Davalieva, K., Makridakis, M., Mullen, W. , Schanstra, J. P., Vlahou, A., Mischak, H. and Frantzi, M. (2020) Molecular changes in tissue proteome during prostate cancer development: proof-of-principle investigation. Diagnostics, 10(9), 655. (doi: 10.3390/diagnostics10090655) (PMID:32878211)

Campbell, R. T. et al. (2020) The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 7(4), pp. 1595-1604. (doi: 10.1002/ehf2.12708) (PMID:32383555) (PMCID:PMC7373887)

Mischak, H. (2020) Datasharing: obsolete? impossible in times of GDPR? Or mandatory in science?! European Journal of Clinical Investigation, 50(8), e13244. (doi: 10.1111/eci.13244) (PMID:32306378)

Pejchinovski, M. and Mischak, H. (2020) Re‐analysis of “Peptidomic analysis of cartilage and subchondral bone in OA patients”. European Journal of Clinical Investigation, 50(8), e13240. (doi: 10.1111/eci.13240) (PMID:32306374)

He, T., Siwy, J., Metzger, J., Mullen, W. , Mischak, H., Schanstra, J. P., Zürbig, P. and Jankowski, V. (2020) Associations of urinary polymeric immunoglobulin receptor peptides in the context of cardio-renal syndrome. Scientific Reports, 10, 8291. (doi: 10.1038/s41598-020-65154-2) (PMID:32427855) (PMCID:PMC7237418)

Tofte, N. et al. (2020) Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology, 8(4), pp. 301-312. (doi: 10.1016/S2213-8587(20)30026-7) (PMID:32135136)

Frantzi, M., Gomez-Gomez, E. and Mischak, H. (2020) Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. Expert Review of Precision Medicine and Drug Development, 5(5), pp. 383-400. (doi: 10.1080/23808993.2020.1804866)

2019

Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi: 10.1161/CIRCHEARTFAILURE.118.005897) (PMID:31104495)

Zürbig, P., Siwy, J. and Mischak, H. (2019) Emerging urine-based proteomic biomarkers as valuable tools in the management of chronic kidney disease. Expert Review of Molecular Diagnostics, 19(10), pp. 853-856. (doi: 10.1080/14737159.2019.1657406) (PMID:31423855)

2018

Huang, Q.-F. et al. (2018) Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients. PLoS ONE, 13(9), e0204439. (doi: 10.1371/journal.pone.0204439) (PMID:30248148) (PMCID:PMC6152976)

Magalhães, P. et al. (2018) Comparison of urine and plasma peptidome indicates selectivity in renal peptide handling. Proteomics Clinical Applications, 12(5), 1700163. (doi: 10.1002/prca.201700163) (PMID:29611317)

Zhang, Z.-Y. et al. (2018) Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. Journal of the American Society of Hypertension, 12(6), 437-447.e4. (doi: 10.1016/j.jash.2018.03.007) (PMID:29681522)

Huang, Q.-F. et al. (2018) Biomarkers to assess right heart pressures in recipients of a heart transplant: a proof-of-concept study. Transplantation Direct, 4(5), e346. (doi: 10.1097/TXD.0000000000000783) (PMID:29796417) (PMCID:PMC5959348)

Lygirou, V., Latosinska, A., Makridakis, M., Mullen, W. , Delles, C. , Schanstra, J. P., Zoidakis, J., Pieske, B., Mischak, H. and Vlahou, A. (2018) Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. Journal of Translational Medicine, 16(1), 104. (doi: 10.1186/s12967-018-1476-9) (PMID:29665821) (PMCID:PMC5905170)

Currie, G. E. et al. (2018) Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. Cardiovascular Diabetology, 17, 50. (doi: 10.1186/s12933-018-0697-9) (PMID:29625564) (PMCID:PMC5889591)

Liu, Y. et al. (2018) Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. Scientific Reports, 8, 5584. (doi: 10.1038/s41598-018-22938-x) (PMID:29615724) (PMCID:PMC5882886)

Belczacka, I., Latosinska, A., Siwy, J., Metzger, J., Merseburger, A. S., Mischak, H., Vlahou, A., Frantzi, M. and Jankowski, V. (2018) Urinary CE-MS peptide marker pattern for detection of solid tumors. Scientific Reports, 8, 5227. (doi: 10.1038/s41598-018-23585-y) (PMID:29588543) (PMCID:PMC5869723)

Dacheva, I. et al. (2018) Proteomanalyse unverdünnter Glaskörperflüssigkeit bei Patienten mit einem Venenastverschluss = [Proteome analysis of undiluted vitreous humor in patients with branch retinal vein occlusion]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 115(3), pp. 203-215. (doi: 10.1007/s00347-017-0469-z) (PMID:28247073)

Latosinska, A., Frantzi, M., Vlahou, A., Merseburger, A. S. and Mischak, H. (2018) Clinical proteomics for precision medicine: the bladder cancer case. Proteomics Clinical Applications, 12(2), 1700074. (doi: 10.1002/prca.201700074) (PMID:28980455)

Vlahou, A., Mischak, H., Zoidakis, J. and Magni, F. (Eds.) (2018) Integration of Omics Approaches and Systems Biology for Clinical Applications. Series: Wiley series on mass spectrometry. John Wiley & Sons, Inc: Hoboken, NJ. ISBN 9781119181149

Pejchinovski, M., Siwy, J., Mullen, W. , Mischak, H., Petri, M.A., Burkly, L.C. and Wei, R. (2018) Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. Lupus, 27(1), pp. 6-16. (doi: 10.1177/0961203317707827) (PMID:28474961)

Krochmal, M., Schanstra, J. P. and Mischak, H. (2018) Urinary peptidomics in kidney disease and drug research. Expert Opinion on Drug Discovery, 13(3), pp. 259-268. (doi: 10.1080/17460441.2018.1418320) (PMID:29240457)

2017

Magalhães, P. et al. (2017) Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies? Scientific Reports, 7, 16915. (doi: 10.1038/s41598-017-17083-w) (PMID:29208969) (PMCID:PMC5717105)

Siwy, J. et al. (2017) Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrology Dialysis Transplantation, 12(1), pp. 2079-2089. (doi: 10.1093/ndt/gfw337) (PMID:27984204)

Krochmal, M. et al. (2017) Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. Scientific Reports, 7, 15160. (doi: 10.1038/s41598-017-15359-9) (PMID:29123184) (PMCID:PMC5680307)

Lindhardt, M. et al. (2017) Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrology Dialysis Transplantation, 32(11), pp. 1866-1873. (doi: 10.1093/ndt/gfw292) (PMID:27507891)

Pontillo, C. et al. (2017) Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker. Kidney International Reports, 2(6), pp. 1066-1075. (doi: 10.1016/j.ekir.2017.06.004) (PMID:29130072) (PMCID:PMC5669285)

Cherney, D., Perkins, B. A., Lytvyn, Y., Heerspink, H., Rodríguez-Ortiz, M. E. and Mischak, H. (2017) The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. PLoS ONE, 12(10), e0186910. (doi: 10.1371/journal.pone.0186910) (PMID:29084249) (PMCID:PMC5662219)

Latosinska, A. et al. (2017) Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention. Oncotarget, 8(41), pp. 69435-69455. (doi: 10.18632/oncotarget.17279) (PMID:28488575)

Zhang, Z.-Y. et al. (2017) A urinary fragment of mucin-1 subunit α is a novel biomarker associated with renal dysfunction in the general population. Kidney International Reports, 2(5), pp. 811-820. (doi: 10.1016/j.ekir.2017.03.012) (PMID:28920100) (PMCID:PMC5589115)

Krochmal, M. et al. (2017) Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis. Scientific Reports, 7, 9091. (doi: 10.1038/s41598-017-09393-w) (PMID:28831120) (PMCID:PMC5567309)

Zhang, Z.‐Y. et al. (2017) Novel urinary peptidomic classifier predicts incident heart failure. Journal of the American Heart Association, 6(8), e005432. (doi: 10.1161/JAHA.116.005432) (PMID:28784649) (PMCID:PMC5586413)

Pontillo, C. and Mischak, H. (2017) Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease. Clinical Kidney Journal, 10(2), pp. 192-201. (doi: 10.1093/ckj/sfx002)

Carleo, A., Chorostowska-Wynimko, J., Koeck, T., Mischak, H., Czajkowska-Malinowska, M., Rozy, A., Welte, T. and Janciauskiene, S. (2017) Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency? International Journal of Chronic Obstructive Pulmonary Disease, 12, pp. 829-837. (doi: 10.2147/COPD.S125240) (PMID:28331304) (PMCID:PMC5352160)

Ortiz, A. et al. (2017) Mitogen-activated protein kinase 14 promotes AKI. Journal of the American Society of Nephrology, 28(3), pp. 823-836. (doi: 10.1681/ASN.2015080898) (PMID:27620989)

Nkuipou-Kenfack, E. et al. (2017) The use of urinary proteomics in the assessment of suitability of mouse models for ageing. PLoS ONE, 12(2), e0166875. (doi: 10.1371/journal.pone.0166875) (PMID:28199320) (PMCID:PMC5310860)

Albalat, A., Mullen, W. , Husi, H. and Mischak, H. (2017) Tissue proteomics in vascular disease. In: Touyz, R. M. and Schiffrin, E. L. (eds.) Hypertension: Methods and Protocols. Series: Methods in molecular biology (1527). Springer New York: New York, pp. 53-60. ISBN 9781493966233 (doi: 10.1007/978-1-4939-6625-7_4)

Siebert, S. , Porter, D., Paterson, C., Hampson, R., Gaya, D., Latosinska, A., Mischak, H., Schanstra, J., Mullen, W. and McInnes, I. (2017) Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Scientific Reports, 7, 40473. (doi: 10.1038/srep40473) (PMID:28091549) (PMCID:PMC5320079)

Mokou, M., Lygirou, V., Vlahou, A. and Mischak, H. (2017) Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. Expert Review of Proteomics, 14(2), pp. 117-136. (doi: 10.1080/14789450.2017.1274653) (PMID:27997814)

2016

Stanley, E., Delatola, E. I., Nkuipou-Kenfack, E., Spooner, W., Kolch, W., Schanstra, J. P., Mischak, H. and Koeck, T. (2016) Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease. BMC Bioinformatics, 17, 496. (doi: 10.1186/s12859-016-1390-1) (PMID:27923348) (PMCID:PMC5139137)

Klein, J., Ramirez-Torres, A., Ericsson, A., Huang, Y., Breuil, B., Siwy, J., Mischak, H., Peng, X.-R., Bascands, J.-L. and Schanstra, J. P. (2016) Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney International, 90(5), pp. 1045-1055. (doi: 10.1016/j.kint.2016.06.023) (PMID:27528550)

Magalhães, P., Mischak, H. and Zürbig, P. (2016) Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases. Current Opinion in Nephrology and Hypertension, 25(6), pp. 494-501. (doi: 10.1097/mnh.0000000000000278) (PMID:27584928)

Martin-Pozuelo, G., Gonzalez-Barrio, R., Barberá, G. G., Albalat, A., García-Alonso, J., Mullen, W. , Mischak, H. and Periag, M. J. (2016) Tomato Juice consumption modifies the urinary peptide profile in Sprague-Dawley rats with induced hepatic steatosis. International Journal of Molecular Sciences, 17(11), 1789. (doi: 10.3390/ijms17111789)

Pontillo, C. and Mischak, H. (2016) Urinary biomarkers to predict CKD: is the future in multi-marker panels? Nephrology Dialysis Transplantation, 31(9), pp. 1373-1375. (doi: 10.1093/ndt/gfv467) (PMID:26932685)

Pena, M. J., Mischak, H. and Heerspink, H. J.L. (2016) Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia, 59(9), pp. 1819-1831. (doi: 10.1007/s00125-016-4001-9) (PMID:27344310) (PMCID:PMC4969331)

Frantzi, M. et al. (2016) Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clinical Cancer Research, 22(16), pp. 4077-4086. (doi: 10.1158/1078-0432.CCR-15-2715) (PMID:27026199)

Schönemeier, B. et al. (2016) Urinary peptide analysis differentiates pancreatic cancer from chronic pancreatitis. Pancreas, 45(7), pp. 1018-1026. (doi: 10.1097/mpa.0000000000000573) (PMID:26784907)

Carrick, E. et al. (2016) Development of a MALDI MS-based platform for early detection of acute kidney injury. Proteomics Clinical Applications, 10(7), pp. 732-742. (doi: 10.1002/prca.201500117) (PMID:27119821) (PMCID:PMC4950042)

Farmakis, D., Koeck, T., Mullen, W. , Parissis, J., Gogas, B. D., Nikolaou, M., Lekakis, J., Mischak, H. and Filippatos, G. (2016) Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates. European Journal of Heart Failure, 18(7), pp. 822-829. (doi: 10.1002/ejhf.544) (PMID:27220540)

Latosinska, A. et al. (2016) Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings. Scientific Reports, 6, 25619. (doi: 10.1038/srep25619) (PMID:27167498) (PMCID:PMC4863247)

Neisius, U. et al. (2016) Urine proteomics in the diagnosis of stable angina. BMC Cardiovascular Disorders, 16, 70. (doi: 10.1186/s12872-016-0246-y) (PMID:27095611) (PMCID:PMC483761)

Klein, J., Bascands, J.-L., Mischak, H. and Schanstra, J. P. (2016) The role of urinary peptidomics in kidney disease research. Kidney International, 89(3), pp. 539-545. (doi: 10.1016/j.kint.2015.10.010) (PMID:26880450)

Stepczynska, A., Schanstra, J. P. and Mischak, H. (2016) Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Bioanalysis, 8(5), pp. 439-455. (doi: 10.4155/bio.16.8) (PMID:26891752)

Bhat, A., Mokou, M., Zoidakis, J., Jankowski, V., Vlahou, A. and Mischak, H. (2016) BcCluster: a bladder cancer database at the molecular level. Bladder Cancer, 2(1), pp. 65-76. (doi: 10.3233/BLC-150024) (PMID:27376128) (PMCID:PMC4927921)

Krochmal, M., Fernandes, M., Filip, S., Pontillo, C., Husi, H., Zoidakis, J., Mischak, H., Vlahou, A. and Jankowski, J. (2016) PeptiCKDdb-peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease. Database, 2016, baw128. (doi: 10.1093/database/baw128) (PMID:27589965) (PMCID:PMC5009324)

Lindhardt, M. et al. (2016) Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open, 6(3), e010310. (doi: 10.1136/bmjopen-2015-010310) (PMID:26936907) (PMCID:PMC4785328)

Magalhães, P., Schanstra, J. P., Carrick, E., Mischak, H. and Zürbig, P. (2016) Urinary biomarkers for renal tract malformations. Expert Review of Proteomics, 13(12), pp. 1121-1129. (doi: 10.1080/14789450.2016.1254555) (PMID:27791437)

Metzger, J., Mullen, W. , Husi, H., Stalmach, A. , Herget-Rosenthal, S., Groesdonk, H., Mischak, H. and Klingele, M. (2016) Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study. Critical Care, 20, 157. (doi: 10.1186/s13054-016-1344-z) (PMID:27230659) (PMCID:PMC4882859)

Rossing, K. et al. (2016) Urinary proteomics pilot study for biomarker discovery and diagnosis in heart failure with reduced ejection fraction. PLoS ONE, 11(6), e0157167. (doi: 10.1371/journal.pone.0157167) (PMID:27308822) (PMCID:PMC4911082)

Zhang, Z.-y. et al. (2016) Diastolic left ventricular function in relation to urinary and serum collagen biomarkers in a general population. PLoS ONE, 11(12), e0167582. (doi: 10.1371/journal.pone.0167582) (PMID:27959898) (PMCID:PMC5154519)

2015

Glorieux, G. et al. (2015) New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrology Dialysis Transplantation, 30(11), pp. 1842-1852. (doi: 10.1093/ndt/gfv254) (PMID:26160894)

Schanstra, J.P. et al. (2015) Diagnosis and prediction of CKD progression by assessment of urinary peptides. Journal of the American Society of Nephrology, 26(8), pp. 1999-2010. (doi: 10.1681/asn.2014050423) (PMID:25589610) (PMCID:PMC4520165)

Nally, J. E., Mullen, W. , Callanan, J. J., Mischak, H. and Albalat, A. (2015) Detection of urinary biomarkers in reservoir hosts of leptospirosis by capillary electrophoresis-mass spectrometry. Proteomics Clinical Applications, 9(5-6), pp. 543-551. (doi: 10.1002/prca.201400205) (PMID:25736478)

Pejchinovski, M., Hrnjez, D., Ramirez-Torres, A., Bitsika, V., Mermelekas, G., Vlahou, A., Zürbig, P., Mischak, H., Metzger, J. and Koeck, T. (2015) Capillary zone electrophoresis on-line coupled to mass spectrometry: a perspective application for clinical proteomics. Proteomics Clinical Applications, 9(5-6), pp. 453-468. (doi: 10.1002/prca.201400113) (PMID:25641766)

Pejchinovski, M., Klein, J., Ramírez-Torres, A., Bitsika, V., Mermelekas, G., Vlahou, A., Mullen, W. , Mischak, H. and Jankowski, V. (2015) Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine. Proteomics Clinical Applications, 9(5-6), pp. 531-542. (doi: 10.1002/prca.201400163) (PMID:25821083)

Mischak, H. (2015) Opponent's comments. Nephrology Dialysis Transplantation, 30(4), pp. 531-532. (doi: 10.1093/ndt/gfv044a) (PMID:25801637)

Mischak, H. (2015) Pro: urine proteomics as a liquid kidney biopsy: no more kidney punctures! Nephrology Dialysis Transplantation, 30(4), pp. 532-537. (doi: 10.1093/ndt/gfv046) (PMID:25801638)

Mischak, H., Delles, C. , Vlahou, A. and Vanholder, R. (2015) Proteomic biomarkers in kidney disease: issues in development and implementation. Nature Reviews Nephrology, 11(4), pp. 221-232. (doi: 10.1038/nrneph.2014.247) (PMID:25643662)

Pontillo, C., Filip, S., Borràs, D. M., Mullen, W. , Vlahou, A. and Mischak, H. (2015) CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clinical Applications, 9(3-4), pp. 322-334. (doi: 10.1002/prca.201400115) (PMID:25641774)

Bhat, A. et al. (2015) Protein interactome of muscle invasive bladder cancer. PLoS ONE, 10(1), e0116404. (doi: 10.1371/journal.pone.0116404) (PMID:25569276) (PMCID:PMC4287622)

Silva, S., Bronze, M. R., Figueira, M. E., Siwy, J., Mischak, H., Combet, E. and Mullen, W. (2015) Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study. American Journal of Clinical Nutrition, 101(4), pp. 44-54. (doi: 10.3945/ajcn.114.094219) (PMID:25527749)

Brown, C. E. et al. (2015) Urinary proteomic biomarkers to predict cardiovascular events. Proteomics Clinical Applications, 9(5-6), pp. 610-617. (doi: 10.1002/prca.201400195) (PMID:25786980)

Filip, S., Vougas, K., Zoidakis, J., Latosinska, A., Mullen, W. , Spasovski, G., Mischak, H., Vlahou, A. and Jankowski, J. (2015) Comparison of depletion strategies for the enrichment of low-abundance proteins in urine. PLoS ONE, 10(7), e0133773. (doi: 10.1371/journal.pone.0133773) (PMID:26208298) (PMCID:PMC4514849)

Jankowski, J., Schanstra, J. and Mischak, H. (2015) Body fluid peptide and protein signatures in diabetic kidney diseases. Nephrology Dialysis Transplantation, 30(Sup 4), iv43-iv53. (doi: 10.1093/ndt/gfv091) (PMID:26209737)

Schanstra, J. P. and Mischak, H. (2015) Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatric Nephrology, 30(5), pp. 713-725. (doi: 10.1007/s00467-014-2790-y)

Stalmach, A. , Husi, H., Mosbahi, K., Albalat, A., Mullen, W. and Mischak, H. (2015) Methods in capillary electrophoresis coupled to mass spectrometry for the identification of clinical proteomic/peptidomic biomarkers in biofluids. Methods in Molecular Biology, 1243, pp. 187-205. (doi: 10.1007/978-1-4939-1872-0_11)

2014

Seetho, I. W. et al. (2014) Urinary proteomics in obstructive sleep apnoea and obesity. European Journal of Clinical Investigation, 44(11), pp. 1104-1115. (doi: 10.1111/eci.12346) (PMID:25267120)

Zhang, Z., Staessen, J. A., Thijs, L., Gu, Y., Liu, Y., Jacobs, L., Koeck, T., Zürbig, P., Mischak, H. and Kuznetsova, T. (2014) Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population. International Journal of Cardiology, 176(1), pp. 158-165. (doi: 10.1016/j.ijcard.2014.07.014) (PMID:25065337) (PMCID:PMC4155932)

Siwy, J. et al. (2014) Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrology Dialysis Transplantation, 29(8), pp. 1563-1570. (doi: 10.1093/ndt/gfu039)

Husi, H., Van Agtmael, T. , Mullen, W. , Bahlmann, F. H., Schanstra, J. P., Vlahou, A., Delles, C. , Perco, P. and Mischak, H. (2014) Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circulation: Cardiovascular Genetics, 7(2), pp. 161-170. (doi: 10.1161/CIRCGENETICS.113.000196)

Klein, J., Papadopoulos, T., Mischak, H. and Mullen, W. (2014) Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis, 35(7), pp. 1060-1064. (doi: 10.1002/elps.201300327)

Mullen, W. , Saigusa, D., Abe, T., Adamski, J. and Mischak, H. (2014) Proteomics and metabolomics as tools to unravel novel culprits and mechanisms of uremic toxicity: instrument or hype? Seminars in Nephrology, 34(2), pp. 180-190. (doi: 10.1016/j.semnephrol.2014.02.009)

Frantzi, M. et al. (2014) Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. Journal of Proteomics, 98C, pp. 44-58. (doi: 10.1016/j.jprot.2013.12.010)

Klein, J., Buffin-Meyer, B., Mullen, W. , Carty, D. M., Delles, C. , Vlahou, A., Mischak, H., Decramer, S., Bascands, J.-L. and Schanstra, J. P. (2014) Clinical proteomics in obstetrics and neonatology. Expert Review of Proteomics, 11(1), pp. 75-89. (doi: 10.1586/14789450.2014.872564)

Albalat, A., Husi, H., Stalmach, A. , Schanstra, J. P. and Mischak, H. (2014) Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications. Bioanalysis, 6(2), pp. 247-66. (doi: 10.4155/bio.13.313)

Filip, S., Zoidakis, J., Vlahou, A. and Mischak, H. (2014) Advances in urinary proteome analysis and applications in systems biology. Bioanalysis, 6(19), pp. 2549-2569. (doi: 10.4155/bio.14.210)

Gu, Y.-M. et al. (2014) The urinary proteome as correlate and predictor of renal function in a population study. Nephrology Dialysis Transplantation, 29(12), pp. 2260-2268. (doi: 10.1093/ndt/gfu234)

Koss, M. J. et al. (2014) Proteomics of vitreous humor of patients with exudative age-related macular degeneration. PLoS ONE, 9(5), e96895. (doi: 10.1371/journal.pone.0096895) (PMID:24828575) (PMCID:PMC4020801)

Nkuipou-Kenfack, E. et al. (2014) Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS ONE, 9(5), e96955. (doi: 10.1371/journal.pone.0096955) (PMID:24817014) (PMCID:PMC4016198)

Stalmach, A. , Johnsson, H., McInnes, I. B. , Husi, H., Klein, J., Dakna, M., Mullen, W. , Mischak, H. and Porter, D. (2014) Identification of urinary peptide biomarkers associated with rheumatoid arthritis. PLoS ONE, 9(8), e104625. (doi: 10.1371/journal.pone.0104625) (PMID:25144639) (PMCID:PMC4140712)

2013

Albalat, A. et al. (2013) Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. Proteomics, 13(20), pp. 2967-2975. (doi: 10.1002/pmic.201300100)

Frantzi, M. et al. (2013) IMAC fractionation in combination with LC–MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. Journal of Proteome Research, 12(9), pp. 3969-3979. (doi: 10.1021/pr400255h)

Klein, J. et al. (2013) Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves(PUV). Science Translational Medicine, 5(198), 198ra106. (doi: 10.1126/scitranslmed.3005807)

Mansor, R., Mullen, W. , Albalat, A., Zerefos, P., Mischak, H., Barrett, D.C., Biggs, A. and Eckersall, P.D. (2013) A peptidomic approach to biomarker discovery for bovine mastitis. Journal of Proteomics, 85, pp. 89-98. (doi: 10.1016/j.jprot.2013.04.027)

Stalmach, A. , Albalat, A., Mullen, W. and Mischak, H. (2013) Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis, 34(11), pp. 1452-1464. (doi: 10.1002/elps.201200708)

Klein, J., Eales, J., Zürbig, P., Vlahou, A., Mischak, H. and Stevens, R. (2013) Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics, 13(7), pp. 1077-1082. (doi: 10.1002/pmic.201200493)

Mischak, H., Vlahou, A. and Ioannidis, J.P.A. (2013) Technical aspects and inter-laboratory variability in native peptide profiling: the CE–MS experience. Clinical Biochemistry, 46(6), pp. 432-443. (doi: 10.1016/j.clinbiochem.2012.09.025)

Roscioni, S.S. et al. (2013) A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia, 56(2), pp. 259-267. (doi: 10.1007/s00125-012-2755-2)

Argiles, A. et al. (2013) CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS ONE, 8(5), e62837. (doi: 10.1371/journal.pone.0062837) (PMID:23690958) (PMCID:PMC3653906)

Dissard, R. et al. (2013) Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice. PLoS ONE, 8(10), e76703. (doi: 10.1371/journal.pone.0076703) (PMID:24098551) (PMCID:PMC3789664)

Husi, H., Sanchez-Niño, M., Delles, C. , Mullen, W. , Vlahou, A., Ortiz, A. and Mischak, H. (2013) A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. BMC Systems Biology, 7(110), (doi: 10.1186/1752-0509-7-110)

Kistler, A.D. et al. (2013) Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS ONE, 8(1), e53016. (doi: 10.1371/journal.pone.0053016) (PMID:23326375) (PMCID:PMC3542378)

Klein, G., Schanstra, J.P., Hoffmann, J., Mischak, H., Siwy, J. and Zimmermann, K. (2013) Proteomics as a quality control tool of pharmaceutical probiotic bacterial lysate products. PLoS ONE, 8(6), e66682. (doi: 10.1371/journal.pone.0066682) (PMID:23840518) (PMCID:PMC3686750)

Metzger, J. et al. (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut, 62(1), pp. 122-130. (doi: 10.1136/gutjnl-2012-302047)

Mischak, H. (2013) How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS. Proteomics Clinical Applications, 6(9-10), pp. 437-442. (doi: 10.1002/prca.201200027)

Weissinger, E.M. et al. (2013) Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host-disease after allogeneic stem cell transplantation. Leukemia, (doi: 10.1038/leu.2013.210)

2012

Zurbig, P., Jerums, G., Hovind, P., MacIsaac, R.J., Mischak, H., Nielsen, S.E., Panagiotopoulos, S., Persson, F. and Rossing, P. (2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes, 61(12), pp. 3304-3313. (doi: 10.2337/db12-0348)

Molin, L. et al. (2012) A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. Journal of Proteomics, 75(18), pp. 5888-5897. (doi: 10.1016/j.jprot.2012.07.024)

Mischak, H. et al. (2012) Implementation of proteomic biomarkers: making it work. European Journal of Clinical Investigation, 42(9), pp. 1027-1036. (doi: 10.1111/j.1365-2362.2012.02674.x) (PMID:22519700) (PMCID:PMC3464367)

von zur Muhlen, C. et al. (2012) Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Molecular and Cellular Proteomics, 11(7), M111.013847. (doi: 10.1074/mcp.M111.013847)

Mullen, W. , Albalat, A., Gonzalez, J., Zerefos, P., Siwy, J., Franke, J. and Mischak, H. (2012) Performance of different separation methods interfaced in the same MS-reflection TOF detector: a comparison of performance between CE versus HPLC for biomarker analysis. Electrophoresis, 33(4), pp. 567-574. (doi: 10.1002/elps.201100415)

Bandin, F., Siwy, J., Breuil, B., Mischak, H., Bascands, J., Decramer, S. and Schanstra, J.P. (2012) Urinary proteome analysis at 5-year followup of patients with nonoperated ureteropelvic junction obstruction suggests ongoing kidney remodeling. Journal of Urology, 187(3), pp. 1006-1011. (doi: 10.1016/j.juro.2011.10.169)

Dawson, J. , Walters, M. , Delles, C. , Mischak, H. and Mullen, W. (2012) Urinary proteomics to support diagnosis of stroke. PLoS ONE, 7(5), e35879. (doi: 10.1371/journal.pone.0035879) (PMID:22615742) (PMCID:PMC3353991)

Kuznetsova, T., Mischak, H., Mullen, W. and Staessen, J.A. (2012) Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. European Heart Journal, 33(18), pp. 2342-2350. (doi: 10.1093/eurheartj/ehs185)

Rouse, R., Siwy, J., Mullen, W. , Mischak, H., Metzger, J. and Hanig, J. (2012) Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS ONE, 7(4), e34606. (doi: 10.1371/journal.pone.0034606) (PMID:22509332) (PMCID:PMC3324487)

Siwy, J. et al. (2012) Evaluation of the zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS ONE, 7(12), e51334. (doi: 10.1371/journal.pone.0051334) (PMID:23236474) (PMCID:PMC3517416)

2011

Albalat, A., Mischak, H. and Mullen, W. (2011) Urine proteomics in clinical applications: technologies, principal considerations and clinical implementation. Prilozi, 32(1), pp. 13-44.

Lankisch, T.O. et al. (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology, 53(3), pp. 875-884. (doi: 10.1002/hep.24103)

Lopez, L.M., Mullen, W. , Zürbig, P., Harris, S.E., Gow, A.J., Starr, J.M., Porteous, D.J., Mischak, H. and Deary, I.J. (2011) A pilot study of urinary peptides as biomarkers for intelligence in old age. Intelligence, 39(1), pp. 46-53. (doi: 10.1016/j.intell.2010.11.001)

Albalat, A., Mischak, H. and Mullen, W. (2011) Clinical application of urinary proteomics/peptidomics. Expert Review of Proteomics, 8(5), pp. 615-629. (doi: 10.1586/epr.11.46)

Carty, D.M. et al. (2011) Urinary proteomics for prediction of preeclampsia. Hypertension, 57(3), pp. 561-569. (doi: 10.1161/HYPERTENSIONAHA.110.164285)

Kistler, A.D. et al. (2011) A distinct urinary biomarker pattern characteristic of female fabry patients that mirrors response to enzyme replacement therapy. PLoS ONE, 6(6), e20534. (doi: 10.1371/journal.pone.0020534) (PMID:21698285) (PMCID:PMC3115947)

Metzger, J. et al. (2011) Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clinical Applications, 5(5-6), pp. 322-333. (doi: 10.1002/prca.201000153)

Mischak, H., Thongboonkerd, V., Schanstra, J.P. and Vlahou, A. (2011) Renal and Urinary Proteomics. Proteomics Clinical Applications, 5(5-6), pp. 211-213. (doi: 10.1002/prca.201190031)

Mullen, W. , Delles, C. and Mischak, H. (2011) Urinary proteomics in the assessment of chronic kidney disease. Current Opinion in Nephrology and Hypertension, 20(6), pp. 654-661. (doi: 10.1097/MNH.0b013e32834b7ffa)

Mullen, W. , Gonzalez, J., Siwy, J., Franke, J., Sattar, N. , Mullan, A., Roberts, S., Delles, C. , Mischak, H. and Albalat, A. (2011) A pilot study on the effect of short-term consumption of a polyphenol rich drink on biomarkers of coronary artery disease defined by urinary proteomics. Journal of Agricultural and Food Chemistry, 59(24), pp. 12850-12857. (doi: 10.1021/jf203369r) (PMID:22070129)

2010

Dakna, M., Harris, K., Kalousis, A., Carpentier, S., Kolch, W., Schanstra, J. P., Haubitz, M., Vlahou, A., Mischak, H. and Girolami, M. (2010) Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers. BMC Bioinformatics, 11(1), p. 594. (doi: 10.1186/1471-2105-11-594)

Good, D. M. et al. (2010) Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 9(11), pp. 2424-2437. (doi: 10.1074/mcp.M110.001917)

Mischak, H. et al. (2010) Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. Science Translational Medicine, 2(46), 46ps42--. (doi: 10.1126/scitranslmed.3001249)

Alkhalaf, A. et al. (2010) Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE, 5(10), e13421. (doi: 10.1371/journal.pone.0013421) (PMID:20975990) (PMCID:PMC2958112)

Delles, C. et al. (2010) Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. Journal of Hypertension, 28(11), pp. 2316-2322. (doi: 10.1097/HJH.0b013e32833d81b7)

Maahs, D.M. et al. (2010) Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS ONE, 5(9), e13051. (doi: 10.1371/journal.pone.0013051) (PMID:20927192) (PMCID:PMC2946909)

Metzger, J., Kirsch, T., Schiffer, E., Ulger, P., Mentes, E., Brand, K., Weissinger, E.M., Haubitz, M., Mischak, H. and Herget-Rosenthal, S. (2010) Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney International, 78(12), pp. 1252-1262. (doi: 10.1038/ki.2010.322)

Mischak, H., Delles, C. , Klein, J. and Schanstra, J.P. (2010) Urinary Proteomics Based on Capillary Electrophoresis-Coupled Mass Spectrometry in Kidney Disease: Discovery and Validation of Biomarkers, and Clinical Application. Advances in Chronic Kidney Disease, 17(6), pp. 493-506. (doi: 10.1053/j.ackd.2010.09.004)

Mischak, H. et al. (2010) Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clinical Applications, 4(4), pp. 464-478. (doi: 10.1002/prca.200900189)

Mischak, H. and Rossing, P. (2010) Proteomic biomarkers in diabetic nephropathy--reality or future promise? Nephrology Dialysis Transplantation, 25(9), pp. 2843-2845. (doi: 10.1093/ndt/gfq363)

Mischak, H. and Schanstra, J.P. (2010) CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clinical Applications, 5(1-2), pp. 9-23. (doi: 10.1002/prca.201000058)

2009

Dakna, M., He, Z., Yu, W.C., Mischak, H. and Kolch, W. (2009) Technical, bioinformatical and statistical aspects of liquid chromatography–mass spectrometry (LC–MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: A critical assessment. Journal of Chromatography B, 877(13), pp. 1250-1258. (doi: 10.1016/j.jchromb.2008.10.048)

Dhillon, A.S., Yip, Y.Y., Grindlay, G.J., Pakay, J.L., Dangers, M., Hillmann, M., Clark, W., Pitt, A.R., Mischak, H. and Kolch, W. (2009) The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cellular Signalling, 21(11), pp. 1645-1651. (doi: 10.1016/j.cellsig.2009.07.001)[Book Review]

Harris, K., Girolami, M. and Mischak, H. (2009) Definition of valid proteomic biomarkers: a bayesian solution. Lecture Notes in Computer Science, 5780, pp. 137-149. (doi: 10.1007/978-3-642-04031-3_13)

Mischak, H., Coon, J., Novak, J., Weissinger, E., Schanstra, J. and Dominiczak, A. (2009) Capillary Electrophoresis-Mass Spectrometry As A Powerful Tool in Biomarker Discovery and Clinical Diagnosis: An Update of Recent Developments. Mass Spectrometry Reviews, 28(5), pp. 703-724. (doi: 10.1002/mas.20205)

zur Muhlen, C. et al. (2009) Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients. Journal of Proteome Research, 8(1), pp. 335-345. (doi: 10.1021/pr800615t)

2008

Jantos-Siwy, J., Schiffer, E., Brand, K., Schumann, G., Rossing, K., Delles, C. , Mischak, H. and Metzger, J. (2008) Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. Journal of Proteome Research, 8(1), pp. 268-281. (doi: 10.1021/pr800401m) (PMID:19012428)

Jiang, H. et al. (2008) Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proceedings of the National Academy of Sciences of the United States of America, 105(32), pp. 11299-11304. (doi: 10.1073/pnas.0801457105)

Rossing, K., Mischak, H., Dakna, M., Zurbig, P., Novak, J., Julian, B. A., Good, D. M., Coon, J. J., Tarnow, L. and Rossing, P. (2008) Urinary Proteomics in Diabetes and CKD. Journal of the American Society of Nephrology, 19(7), pp. 1283-1290. (doi: 10.1681/ASN.2007091025)

Zimmerli, L.U. et al. (2008) Urinary proteomic biomarkers on coronary artery disease. Molecular and Cellular Proteomics, 7(2), pp. 290-298. (doi: 10.1074/mcp.M700394-MCP200)

Coon, J.J. et al. (2008) CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clinical Applications, 2(7-8), pp. 964-973. (doi: 10.1002/prca.200800024)

2007

Mischak, H. (2007) Method and device for the qualitative and/or quantitative analysis of a protein and/or peptide pattern of a liquid sample that is derived from the human or animal body. .

Articles

Yu, Y.-L. et al. (2024) Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial. Heart, 110(19), pp. 1180-1187. (doi: 10.1136/heartjnl-2023-323796) (PMID:38729636)

Catanese, L. et al. (2024) Differentiating primary and secondary FSGS using non-invasive urine biomarkers. Clinical Kidney Journal, 17(2), sfad296. (doi: 10.1093/ckj/sfad296) (PMID:38313685) (PMCID:PMC10833144)

Mischak, H. (2023) Comment on ‘A classifier based on 273 urinary peptides predicts early renal damage in primary hypertension’ by Lin et al. Journal of Hypertension, 41(10), p. 1666. (doi: 10.1097/HJH.0000000000003489) (PMID:37642594)

De Beer, D., Mels, C. M.C., Schutte, A. E., Delles, C. , Mary, S. , Mullen, W. , Latosinska, A., Mischak, H. and Kruger, R. (2023) Identifying a urinary peptidomics profile for hypertension in young adults: the African-PREDICT study. Proteomics, 23(11), 2200444. (doi: 10.1002/pmic.202200444) (PMID:36943111)

Degenaar, A., Jacobs, A., Kruger, R., Delles, C. , Mischak, H. and Mels, C.M.C. (2023) Cardiovascular risk and kidney function profiling using conventional and novel biomarkers in young adults: the African-PREDICT study. BMC Nephrology, 24, 96. (doi: 10.1186/s12882-023-03100-w) (PMID:37055746) (PMCID:PMC10103421)

Rotbain Curovic, V. et al. (2023) Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – a post-hoc analysis of the PRIORITY randomized clinical trial. Journal of Diabetes and its Complications, 37(4), 108433. (doi: 10.1016/j.jdiacomp.2023.108433) (PMID:36841085)

Mokou, M., Mischak, H. and Frantzi, M. (2023) Statistical determination of cancer biomarkers: moving forward clinically. Expert Review of Molecular Diagnostics, 23(3), pp. 187-189. (doi: 10.1080/14737159.2023.2187290) (PMID:36877119)

de Beer, D., Mels, C. M. C., Schutte, A. E., Delles, C. , Mary, S. , Mullen, W. , Mischak, H. and Kruger, R. (2023) A urinary peptidomics approach for early stages of cardiovascular disease risk: the African-PREDICT study. Hypertension Research, 46(2), pp. 485-494. (doi: 10.1038/s41440-022-01097-7) (PMID:36396816)

Frantzi, M. et al. (2023) Mass spectrometry-based biomarkers to detect prostate cancer: a multicentric study based on non-invasive urine collection without prior digital rectal examination. Cancers, 15(4), 1166. (doi: 10.3390/cancers15041166) (PMID:36831508) (PMCID:PMC9954607)

Frantzi, M. et al. (2022) Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancer. World Journal of Urology, 40(9), pp. 2195-2203. (doi: 10.1007/s00345-022-04077-1) (PMID:35841414)

O’Connell, S. P. et al. (2022) A model to detect significant prostate cancer integrating urinary peptide and extracellular vesicle RNA data. Cancers, 14(8), 1995. (doi: 10.3390/cancers14081995) (PMID:35454901) (PMCID:PMC9027643)

Wei, D. et al. (2022) The novel proteomic signature for cardiac allograft vasculopathy. ESC Heart Failure, 9(2), pp. 1216-1227. (doi: 10.1002/ehf2.13796) (PMID:35005846) (PMCID:PMC8934921)

He, T. et al. (2021) Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 23(11), pp. 1875-1887. (doi: 10.1002/ejhf.2195) (PMID:33881206)

Hupe, M. C., Hempel, M. C., Rodler, S., Frantzi, M., Mischak, H., Merseburger, A. S., Stief, C. G. and Chaloupka, M. (2021) Diagnostische marker in der Urologie. Urologe, 60(10), pp. 1323-1330. (doi: 10.1007/s00120-021-01568-8) (PMID:34156515)

He, T. et al. (2021) Serum and urinary biomarkers of collagen type‐I turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 11(1), e267. (doi: 10.1002/ctm2.267) (PMID:33463057) (PMCID:PMC7803349)

Mokou, M. et al. (2020) A novel pipeline for drug repurposing for bladder cancer based on patients’ omics signatures. Cancers, 12(12), 3519. (doi: 10.3390/cancers12123519) (PMID:33255925) (PMCID:PMC7759896)

Frantzi, M., Hupe, M. C., Merseburger, A. S., Schanstra, J. P., Mischak, H. and Latosinska, A. (2020) Omics derived biomarkers and novel drug targets for improved intervention in advanced prostate cancer. Diagnostics, 10(9), 658. (doi: 10.3390/diagnostics10090658) (PMID:32878288)

Latosinska, A., Davalieva, K., Makridakis, M., Mullen, W. , Schanstra, J. P., Vlahou, A., Mischak, H. and Frantzi, M. (2020) Molecular changes in tissue proteome during prostate cancer development: proof-of-principle investigation. Diagnostics, 10(9), 655. (doi: 10.3390/diagnostics10090655) (PMID:32878211)

Campbell, R. T. et al. (2020) The novel urinary proteomic classifier HF1 has similar diagnostic and prognostic utility to BNP in heart failure. ESC Heart Failure, 7(4), pp. 1595-1604. (doi: 10.1002/ehf2.12708) (PMID:32383555) (PMCID:PMC7373887)

Mischak, H. (2020) Datasharing: obsolete? impossible in times of GDPR? Or mandatory in science?! European Journal of Clinical Investigation, 50(8), e13244. (doi: 10.1111/eci.13244) (PMID:32306378)

Pejchinovski, M. and Mischak, H. (2020) Re‐analysis of “Peptidomic analysis of cartilage and subchondral bone in OA patients”. European Journal of Clinical Investigation, 50(8), e13240. (doi: 10.1111/eci.13240) (PMID:32306374)

He, T., Siwy, J., Metzger, J., Mullen, W. , Mischak, H., Schanstra, J. P., Zürbig, P. and Jankowski, V. (2020) Associations of urinary polymeric immunoglobulin receptor peptides in the context of cardio-renal syndrome. Scientific Reports, 10, 8291. (doi: 10.1038/s41598-020-65154-2) (PMID:32427855) (PMCID:PMC7237418)

Tofte, N. et al. (2020) Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes and Endocrinology, 8(4), pp. 301-312. (doi: 10.1016/S2213-8587(20)30026-7) (PMID:32135136)

Frantzi, M., Gomez-Gomez, E. and Mischak, H. (2020) Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. Expert Review of Precision Medicine and Drug Development, 5(5), pp. 383-400. (doi: 10.1080/23808993.2020.1804866)

Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. Circulation, 12(5), e005897. (doi: 10.1161/CIRCHEARTFAILURE.118.005897) (PMID:31104495)

Zürbig, P., Siwy, J. and Mischak, H. (2019) Emerging urine-based proteomic biomarkers as valuable tools in the management of chronic kidney disease. Expert Review of Molecular Diagnostics, 19(10), pp. 853-856. (doi: 10.1080/14737159.2019.1657406) (PMID:31423855)

Huang, Q.-F. et al. (2018) Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients. PLoS ONE, 13(9), e0204439. (doi: 10.1371/journal.pone.0204439) (PMID:30248148) (PMCID:PMC6152976)

Magalhães, P. et al. (2018) Comparison of urine and plasma peptidome indicates selectivity in renal peptide handling. Proteomics Clinical Applications, 12(5), 1700163. (doi: 10.1002/prca.201700163) (PMID:29611317)

Zhang, Z.-Y. et al. (2018) Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction. Journal of the American Society of Hypertension, 12(6), 437-447.e4. (doi: 10.1016/j.jash.2018.03.007) (PMID:29681522)

Huang, Q.-F. et al. (2018) Biomarkers to assess right heart pressures in recipients of a heart transplant: a proof-of-concept study. Transplantation Direct, 4(5), e346. (doi: 10.1097/TXD.0000000000000783) (PMID:29796417) (PMCID:PMC5959348)

Lygirou, V., Latosinska, A., Makridakis, M., Mullen, W. , Delles, C. , Schanstra, J. P., Zoidakis, J., Pieske, B., Mischak, H. and Vlahou, A. (2018) Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. Journal of Translational Medicine, 16(1), 104. (doi: 10.1186/s12967-018-1476-9) (PMID:29665821) (PMCID:PMC5905170)

Currie, G. E. et al. (2018) Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. Cardiovascular Diabetology, 17, 50. (doi: 10.1186/s12933-018-0697-9) (PMID:29625564) (PMCID:PMC5889591)

Liu, Y. et al. (2018) Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease. Scientific Reports, 8, 5584. (doi: 10.1038/s41598-018-22938-x) (PMID:29615724) (PMCID:PMC5882886)

Belczacka, I., Latosinska, A., Siwy, J., Metzger, J., Merseburger, A. S., Mischak, H., Vlahou, A., Frantzi, M. and Jankowski, V. (2018) Urinary CE-MS peptide marker pattern for detection of solid tumors. Scientific Reports, 8, 5227. (doi: 10.1038/s41598-018-23585-y) (PMID:29588543) (PMCID:PMC5869723)

Dacheva, I. et al. (2018) Proteomanalyse unverdünnter Glaskörperflüssigkeit bei Patienten mit einem Venenastverschluss = [Proteome analysis of undiluted vitreous humor in patients with branch retinal vein occlusion]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 115(3), pp. 203-215. (doi: 10.1007/s00347-017-0469-z) (PMID:28247073)

Latosinska, A., Frantzi, M., Vlahou, A., Merseburger, A. S. and Mischak, H. (2018) Clinical proteomics for precision medicine: the bladder cancer case. Proteomics Clinical Applications, 12(2), 1700074. (doi: 10.1002/prca.201700074) (PMID:28980455)

Pejchinovski, M., Siwy, J., Mullen, W. , Mischak, H., Petri, M.A., Burkly, L.C. and Wei, R. (2018) Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus. Lupus, 27(1), pp. 6-16. (doi: 10.1177/0961203317707827) (PMID:28474961)

Krochmal, M., Schanstra, J. P. and Mischak, H. (2018) Urinary peptidomics in kidney disease and drug research. Expert Opinion on Drug Discovery, 13(3), pp. 259-268. (doi: 10.1080/17460441.2018.1418320) (PMID:29240457)

Magalhães, P. et al. (2017) Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies? Scientific Reports, 7, 16915. (doi: 10.1038/s41598-017-17083-w) (PMID:29208969) (PMCID:PMC5717105)

Siwy, J. et al. (2017) Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrology Dialysis Transplantation, 12(1), pp. 2079-2089. (doi: 10.1093/ndt/gfw337) (PMID:27984204)

Krochmal, M. et al. (2017) Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. Scientific Reports, 7, 15160. (doi: 10.1038/s41598-017-15359-9) (PMID:29123184) (PMCID:PMC5680307)

Lindhardt, M. et al. (2017) Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrology Dialysis Transplantation, 32(11), pp. 1866-1873. (doi: 10.1093/ndt/gfw292) (PMID:27507891)

Pontillo, C. et al. (2017) Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker. Kidney International Reports, 2(6), pp. 1066-1075. (doi: 10.1016/j.ekir.2017.06.004) (PMID:29130072) (PMCID:PMC5669285)

Cherney, D., Perkins, B. A., Lytvyn, Y., Heerspink, H., Rodríguez-Ortiz, M. E. and Mischak, H. (2017) The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. PLoS ONE, 12(10), e0186910. (doi: 10.1371/journal.pone.0186910) (PMID:29084249) (PMCID:PMC5662219)

Latosinska, A. et al. (2017) Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention. Oncotarget, 8(41), pp. 69435-69455. (doi: 10.18632/oncotarget.17279) (PMID:28488575)

Zhang, Z.-Y. et al. (2017) A urinary fragment of mucin-1 subunit α is a novel biomarker associated with renal dysfunction in the general population. Kidney International Reports, 2(5), pp. 811-820. (doi: 10.1016/j.ekir.2017.03.012) (PMID:28920100) (PMCID:PMC5589115)

Krochmal, M. et al. (2017) Identification of novel molecular signatures of IgA nephropathy through an integrative -omics analysis. Scientific Reports, 7, 9091. (doi: 10.1038/s41598-017-09393-w) (PMID:28831120) (PMCID:PMC5567309)

Zhang, Z.‐Y. et al. (2017) Novel urinary peptidomic classifier predicts incident heart failure. Journal of the American Heart Association, 6(8), e005432. (doi: 10.1161/JAHA.116.005432) (PMID:28784649) (PMCID:PMC5586413)

Pontillo, C. and Mischak, H. (2017) Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease. Clinical Kidney Journal, 10(2), pp. 192-201. (doi: 10.1093/ckj/sfx002)

Carleo, A., Chorostowska-Wynimko, J., Koeck, T., Mischak, H., Czajkowska-Malinowska, M., Rozy, A., Welte, T. and Janciauskiene, S. (2017) Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency? International Journal of Chronic Obstructive Pulmonary Disease, 12, pp. 829-837. (doi: 10.2147/COPD.S125240) (PMID:28331304) (PMCID:PMC5352160)

Ortiz, A. et al. (2017) Mitogen-activated protein kinase 14 promotes AKI. Journal of the American Society of Nephrology, 28(3), pp. 823-836. (doi: 10.1681/ASN.2015080898) (PMID:27620989)

Nkuipou-Kenfack, E. et al. (2017) The use of urinary proteomics in the assessment of suitability of mouse models for ageing. PLoS ONE, 12(2), e0166875. (doi: 10.1371/journal.pone.0166875) (PMID:28199320) (PMCID:PMC5310860)

Siebert, S. , Porter, D., Paterson, C., Hampson, R., Gaya, D., Latosinska, A., Mischak, H., Schanstra, J., Mullen, W. and McInnes, I. (2017) Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Scientific Reports, 7, 40473. (doi: 10.1038/srep40473) (PMID:28091549) (PMCID:PMC5320079)

Mokou, M., Lygirou, V., Vlahou, A. and Mischak, H. (2017) Proteomics in cardiovascular disease: recent progress and clinical implication and implementation. Expert Review of Proteomics, 14(2), pp. 117-136. (doi: 10.1080/14789450.2017.1274653) (PMID:27997814)

Stanley, E., Delatola, E. I., Nkuipou-Kenfack, E., Spooner, W., Kolch, W., Schanstra, J. P., Mischak, H. and Koeck, T. (2016) Comparison of different statistical approaches for urinary peptide biomarker detection in the context of coronary artery disease. BMC Bioinformatics, 17, 496. (doi: 10.1186/s12859-016-1390-1) (PMID:27923348) (PMCID:PMC5139137)

Klein, J., Ramirez-Torres, A., Ericsson, A., Huang, Y., Breuil, B., Siwy, J., Mischak, H., Peng, X.-R., Bascands, J.-L. and Schanstra, J. P. (2016) Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney International, 90(5), pp. 1045-1055. (doi: 10.1016/j.kint.2016.06.023) (PMID:27528550)

Magalhães, P., Mischak, H. and Zürbig, P. (2016) Urinary proteomics using capillary electrophoresis coupled to mass spectrometry for diagnosis and prognosis in kidney diseases. Current Opinion in Nephrology and Hypertension, 25(6), pp. 494-501. (doi: 10.1097/mnh.0000000000000278) (PMID:27584928)

Martin-Pozuelo, G., Gonzalez-Barrio, R., Barberá, G. G., Albalat, A., García-Alonso, J., Mullen, W. , Mischak, H. and Periag, M. J. (2016) Tomato Juice consumption modifies the urinary peptide profile in Sprague-Dawley rats with induced hepatic steatosis. International Journal of Molecular Sciences, 17(11), 1789. (doi: 10.3390/ijms17111789)

Pontillo, C. and Mischak, H. (2016) Urinary biomarkers to predict CKD: is the future in multi-marker panels? Nephrology Dialysis Transplantation, 31(9), pp. 1373-1375. (doi: 10.1093/ndt/gfv467) (PMID:26932685)

Pena, M. J., Mischak, H. and Heerspink, H. J.L. (2016) Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease. Diabetologia, 59(9), pp. 1819-1831. (doi: 10.1007/s00125-016-4001-9) (PMID:27344310) (PMCID:PMC4969331)

Frantzi, M. et al. (2016) Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clinical Cancer Research, 22(16), pp. 4077-4086. (doi: 10.1158/1078-0432.CCR-15-2715) (PMID:27026199)

Schönemeier, B. et al. (2016) Urinary peptide analysis differentiates pancreatic cancer from chronic pancreatitis. Pancreas, 45(7), pp. 1018-1026. (doi: 10.1097/mpa.0000000000000573) (PMID:26784907)

Carrick, E. et al. (2016) Development of a MALDI MS-based platform for early detection of acute kidney injury. Proteomics Clinical Applications, 10(7), pp. 732-742. (doi: 10.1002/prca.201500117) (PMID:27119821) (PMCID:PMC4950042)

Farmakis, D., Koeck, T., Mullen, W. , Parissis, J., Gogas, B. D., Nikolaou, M., Lekakis, J., Mischak, H. and Filippatos, G. (2016) Urine proteome analysis in heart failure with reduced ejection fraction complicated by chronic kidney disease: feasibility, and clinical and pathogenetic correlates. European Journal of Heart Failure, 18(7), pp. 822-829. (doi: 10.1002/ejhf.544) (PMID:27220540)

Latosinska, A. et al. (2016) Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of -omics findings. Scientific Reports, 6, 25619. (doi: 10.1038/srep25619) (PMID:27167498) (PMCID:PMC4863247)

Neisius, U. et al. (2016) Urine proteomics in the diagnosis of stable angina. BMC Cardiovascular Disorders, 16, 70. (doi: 10.1186/s12872-016-0246-y) (PMID:27095611) (PMCID:PMC483761)

Klein, J., Bascands, J.-L., Mischak, H. and Schanstra, J. P. (2016) The role of urinary peptidomics in kidney disease research. Kidney International, 89(3), pp. 539-545. (doi: 10.1016/j.kint.2015.10.010) (PMID:26880450)

Stepczynska, A., Schanstra, J. P. and Mischak, H. (2016) Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Bioanalysis, 8(5), pp. 439-455. (doi: 10.4155/bio.16.8) (PMID:26891752)

Bhat, A., Mokou, M., Zoidakis, J., Jankowski, V., Vlahou, A. and Mischak, H. (2016) BcCluster: a bladder cancer database at the molecular level. Bladder Cancer, 2(1), pp. 65-76. (doi: 10.3233/BLC-150024) (PMID:27376128) (PMCID:PMC4927921)

Krochmal, M., Fernandes, M., Filip, S., Pontillo, C., Husi, H., Zoidakis, J., Mischak, H., Vlahou, A. and Jankowski, J. (2016) PeptiCKDdb-peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease. Database, 2016, baw128. (doi: 10.1093/database/baw128) (PMID:27589965) (PMCID:PMC5009324)

Lindhardt, M. et al. (2016) Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open, 6(3), e010310. (doi: 10.1136/bmjopen-2015-010310) (PMID:26936907) (PMCID:PMC4785328)

Magalhães, P., Schanstra, J. P., Carrick, E., Mischak, H. and Zürbig, P. (2016) Urinary biomarkers for renal tract malformations. Expert Review of Proteomics, 13(12), pp. 1121-1129. (doi: 10.1080/14789450.2016.1254555) (PMID:27791437)

Metzger, J., Mullen, W. , Husi, H., Stalmach, A. , Herget-Rosenthal, S., Groesdonk, H., Mischak, H. and Klingele, M. (2016) Acute kidney injury prediction in cardiac surgery patients by a urinary peptide pattern: a case-control validation study. Critical Care, 20, 157. (doi: 10.1186/s13054-016-1344-z) (PMID:27230659) (PMCID:PMC4882859)

Rossing, K. et al. (2016) Urinary proteomics pilot study for biomarker discovery and diagnosis in heart failure with reduced ejection fraction. PLoS ONE, 11(6), e0157167. (doi: 10.1371/journal.pone.0157167) (PMID:27308822) (PMCID:PMC4911082)

Zhang, Z.-y. et al. (2016) Diastolic left ventricular function in relation to urinary and serum collagen biomarkers in a general population. PLoS ONE, 11(12), e0167582. (doi: 10.1371/journal.pone.0167582) (PMID:27959898) (PMCID:PMC5154519)

Glorieux, G. et al. (2015) New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrology Dialysis Transplantation, 30(11), pp. 1842-1852. (doi: 10.1093/ndt/gfv254) (PMID:26160894)

Schanstra, J.P. et al. (2015) Diagnosis and prediction of CKD progression by assessment of urinary peptides. Journal of the American Society of Nephrology, 26(8), pp. 1999-2010. (doi: 10.1681/asn.2014050423) (PMID:25589610) (PMCID:PMC4520165)

Nally, J. E., Mullen, W. , Callanan, J. J., Mischak, H. and Albalat, A. (2015) Detection of urinary biomarkers in reservoir hosts of leptospirosis by capillary electrophoresis-mass spectrometry. Proteomics Clinical Applications, 9(5-6), pp. 543-551. (doi: 10.1002/prca.201400205) (PMID:25736478)

Pejchinovski, M., Hrnjez, D., Ramirez-Torres, A., Bitsika, V., Mermelekas, G., Vlahou, A., Zürbig, P., Mischak, H., Metzger, J. and Koeck, T. (2015) Capillary zone electrophoresis on-line coupled to mass spectrometry: a perspective application for clinical proteomics. Proteomics Clinical Applications, 9(5-6), pp. 453-468. (doi: 10.1002/prca.201400113) (PMID:25641766)

Pejchinovski, M., Klein, J., Ramírez-Torres, A., Bitsika, V., Mermelekas, G., Vlahou, A., Mullen, W. , Mischak, H. and Jankowski, V. (2015) Comparison of higher energy collisional dissociation and collision-induced dissociation MS/MS sequencing methods for identification of naturally occurring peptides in human urine. Proteomics Clinical Applications, 9(5-6), pp. 531-542. (doi: 10.1002/prca.201400163) (PMID:25821083)

Mischak, H. (2015) Opponent's comments. Nephrology Dialysis Transplantation, 30(4), pp. 531-532. (doi: 10.1093/ndt/gfv044a) (PMID:25801637)

Mischak, H. (2015) Pro: urine proteomics as a liquid kidney biopsy: no more kidney punctures! Nephrology Dialysis Transplantation, 30(4), pp. 532-537. (doi: 10.1093/ndt/gfv046) (PMID:25801638)

Mischak, H., Delles, C. , Vlahou, A. and Vanholder, R. (2015) Proteomic biomarkers in kidney disease: issues in development and implementation. Nature Reviews Nephrology, 11(4), pp. 221-232. (doi: 10.1038/nrneph.2014.247) (PMID:25643662)

Pontillo, C., Filip, S., Borràs, D. M., Mullen, W. , Vlahou, A. and Mischak, H. (2015) CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clinical Applications, 9(3-4), pp. 322-334. (doi: 10.1002/prca.201400115) (PMID:25641774)

Bhat, A. et al. (2015) Protein interactome of muscle invasive bladder cancer. PLoS ONE, 10(1), e0116404. (doi: 10.1371/journal.pone.0116404) (PMID:25569276) (PMCID:PMC4287622)

Silva, S., Bronze, M. R., Figueira, M. E., Siwy, J., Mischak, H., Combet, E. and Mullen, W. (2015) Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study. American Journal of Clinical Nutrition, 101(4), pp. 44-54. (doi: 10.3945/ajcn.114.094219) (PMID:25527749)

Brown, C. E. et al. (2015) Urinary proteomic biomarkers to predict cardiovascular events. Proteomics Clinical Applications, 9(5-6), pp. 610-617. (doi: 10.1002/prca.201400195) (PMID:25786980)

Filip, S., Vougas, K., Zoidakis, J., Latosinska, A., Mullen, W. , Spasovski, G., Mischak, H., Vlahou, A. and Jankowski, J. (2015) Comparison of depletion strategies for the enrichment of low-abundance proteins in urine. PLoS ONE, 10(7), e0133773. (doi: 10.1371/journal.pone.0133773) (PMID:26208298) (PMCID:PMC4514849)

Jankowski, J., Schanstra, J. and Mischak, H. (2015) Body fluid peptide and protein signatures in diabetic kidney diseases. Nephrology Dialysis Transplantation, 30(Sup 4), iv43-iv53. (doi: 10.1093/ndt/gfv091) (PMID:26209737)

Schanstra, J. P. and Mischak, H. (2015) Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatric Nephrology, 30(5), pp. 713-725. (doi: 10.1007/s00467-014-2790-y)

Stalmach, A. , Husi, H., Mosbahi, K., Albalat, A., Mullen, W. and Mischak, H. (2015) Methods in capillary electrophoresis coupled to mass spectrometry for the identification of clinical proteomic/peptidomic biomarkers in biofluids. Methods in Molecular Biology, 1243, pp. 187-205. (doi: 10.1007/978-1-4939-1872-0_11)

Seetho, I. W. et al. (2014) Urinary proteomics in obstructive sleep apnoea and obesity. European Journal of Clinical Investigation, 44(11), pp. 1104-1115. (doi: 10.1111/eci.12346) (PMID:25267120)

Zhang, Z., Staessen, J. A., Thijs, L., Gu, Y., Liu, Y., Jacobs, L., Koeck, T., Zürbig, P., Mischak, H. and Kuznetsova, T. (2014) Left ventricular diastolic function in relation to the urinary proteome: a proof-of-concept study in a general population. International Journal of Cardiology, 176(1), pp. 158-165. (doi: 10.1016/j.ijcard.2014.07.014) (PMID:25065337) (PMCID:PMC4155932)

Siwy, J. et al. (2014) Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrology Dialysis Transplantation, 29(8), pp. 1563-1570. (doi: 10.1093/ndt/gfu039)

Husi, H., Van Agtmael, T. , Mullen, W. , Bahlmann, F. H., Schanstra, J. P., Vlahou, A., Delles, C. , Perco, P. and Mischak, H. (2014) Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease. Circulation: Cardiovascular Genetics, 7(2), pp. 161-170. (doi: 10.1161/CIRCGENETICS.113.000196)

Klein, J., Papadopoulos, T., Mischak, H. and Mullen, W. (2014) Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis, 35(7), pp. 1060-1064. (doi: 10.1002/elps.201300327)

Mullen, W. , Saigusa, D., Abe, T., Adamski, J. and Mischak, H. (2014) Proteomics and metabolomics as tools to unravel novel culprits and mechanisms of uremic toxicity: instrument or hype? Seminars in Nephrology, 34(2), pp. 180-190. (doi: 10.1016/j.semnephrol.2014.02.009)

Frantzi, M. et al. (2014) Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. Journal of Proteomics, 98C, pp. 44-58. (doi: 10.1016/j.jprot.2013.12.010)

Klein, J., Buffin-Meyer, B., Mullen, W. , Carty, D. M., Delles, C. , Vlahou, A., Mischak, H., Decramer, S., Bascands, J.-L. and Schanstra, J. P. (2014) Clinical proteomics in obstetrics and neonatology. Expert Review of Proteomics, 11(1), pp. 75-89. (doi: 10.1586/14789450.2014.872564)

Albalat, A., Husi, H., Stalmach, A. , Schanstra, J. P. and Mischak, H. (2014) Classical MALDI-MS versus CE-based ESI-MS proteomic profiling in urine for clinical applications. Bioanalysis, 6(2), pp. 247-66. (doi: 10.4155/bio.13.313)

Filip, S., Zoidakis, J., Vlahou, A. and Mischak, H. (2014) Advances in urinary proteome analysis and applications in systems biology. Bioanalysis, 6(19), pp. 2549-2569. (doi: 10.4155/bio.14.210)

Gu, Y.-M. et al. (2014) The urinary proteome as correlate and predictor of renal function in a population study. Nephrology Dialysis Transplantation, 29(12), pp. 2260-2268. (doi: 10.1093/ndt/gfu234)

Koss, M. J. et al. (2014) Proteomics of vitreous humor of patients with exudative age-related macular degeneration. PLoS ONE, 9(5), e96895. (doi: 10.1371/journal.pone.0096895) (PMID:24828575) (PMCID:PMC4020801)

Nkuipou-Kenfack, E. et al. (2014) Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS ONE, 9(5), e96955. (doi: 10.1371/journal.pone.0096955) (PMID:24817014) (PMCID:PMC4016198)

Stalmach, A. , Johnsson, H., McInnes, I. B. , Husi, H., Klein, J., Dakna, M., Mullen, W. , Mischak, H. and Porter, D. (2014) Identification of urinary peptide biomarkers associated with rheumatoid arthritis. PLoS ONE, 9(8), e104625. (doi: 10.1371/journal.pone.0104625) (PMID:25144639) (PMCID:PMC4140712)

Albalat, A. et al. (2013) Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment. Proteomics, 13(20), pp. 2967-2975. (doi: 10.1002/pmic.201300100)

Frantzi, M. et al. (2013) IMAC fractionation in combination with LC–MS reveals H2B and NIF-1 peptides as potential bladder cancer biomarkers. Journal of Proteome Research, 12(9), pp. 3969-3979. (doi: 10.1021/pr400255h)

Klein, J. et al. (2013) Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves(PUV). Science Translational Medicine, 5(198), 198ra106. (doi: 10.1126/scitranslmed.3005807)

Mansor, R., Mullen, W. , Albalat, A., Zerefos, P., Mischak, H., Barrett, D.C., Biggs, A. and Eckersall, P.D. (2013) A peptidomic approach to biomarker discovery for bovine mastitis. Journal of Proteomics, 85, pp. 89-98. (doi: 10.1016/j.jprot.2013.04.027)

Stalmach, A. , Albalat, A., Mullen, W. and Mischak, H. (2013) Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis, 34(11), pp. 1452-1464. (doi: 10.1002/elps.201200708)

Klein, J., Eales, J., Zürbig, P., Vlahou, A., Mischak, H. and Stevens, R. (2013) Proteasix: a tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics, 13(7), pp. 1077-1082. (doi: 10.1002/pmic.201200493)

Mischak, H., Vlahou, A. and Ioannidis, J.P.A. (2013) Technical aspects and inter-laboratory variability in native peptide profiling: the CE–MS experience. Clinical Biochemistry, 46(6), pp. 432-443. (doi: 10.1016/j.clinbiochem.2012.09.025)

Roscioni, S.S. et al. (2013) A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia, 56(2), pp. 259-267. (doi: 10.1007/s00125-012-2755-2)

Argiles, A. et al. (2013) CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS ONE, 8(5), e62837. (doi: 10.1371/journal.pone.0062837) (PMID:23690958) (PMCID:PMC3653906)

Dissard, R. et al. (2013) Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice. PLoS ONE, 8(10), e76703. (doi: 10.1371/journal.pone.0076703) (PMID:24098551) (PMCID:PMC3789664)

Husi, H., Sanchez-Niño, M., Delles, C. , Mullen, W. , Vlahou, A., Ortiz, A. and Mischak, H. (2013) A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI. BMC Systems Biology, 7(110), (doi: 10.1186/1752-0509-7-110)

Kistler, A.D. et al. (2013) Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS ONE, 8(1), e53016. (doi: 10.1371/journal.pone.0053016) (PMID:23326375) (PMCID:PMC3542378)

Klein, G., Schanstra, J.P., Hoffmann, J., Mischak, H., Siwy, J. and Zimmermann, K. (2013) Proteomics as a quality control tool of pharmaceutical probiotic bacterial lysate products. PLoS ONE, 8(6), e66682. (doi: 10.1371/journal.pone.0066682) (PMID:23840518) (PMCID:PMC3686750)

Metzger, J. et al. (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut, 62(1), pp. 122-130. (doi: 10.1136/gutjnl-2012-302047)

Mischak, H. (2013) How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS. Proteomics Clinical Applications, 6(9-10), pp. 437-442. (doi: 10.1002/prca.201200027)

Weissinger, E.M. et al. (2013) Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host-disease after allogeneic stem cell transplantation. Leukemia, (doi: 10.1038/leu.2013.210)

Zurbig, P., Jerums, G., Hovind, P., MacIsaac, R.J., Mischak, H., Nielsen, S.E., Panagiotopoulos, S., Persson, F. and Rossing, P. (2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes, 61(12), pp. 3304-3313. (doi: 10.2337/db12-0348)

Molin, L. et al. (2012) A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. Journal of Proteomics, 75(18), pp. 5888-5897. (doi: 10.1016/j.jprot.2012.07.024)

Mischak, H. et al. (2012) Implementation of proteomic biomarkers: making it work. European Journal of Clinical Investigation, 42(9), pp. 1027-1036. (doi: 10.1111/j.1365-2362.2012.02674.x) (PMID:22519700) (PMCID:PMC3464367)

von zur Muhlen, C. et al. (2012) Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Molecular and Cellular Proteomics, 11(7), M111.013847. (doi: 10.1074/mcp.M111.013847)

Mullen, W. , Albalat, A., Gonzalez, J., Zerefos, P., Siwy, J., Franke, J. and Mischak, H. (2012) Performance of different separation methods interfaced in the same MS-reflection TOF detector: a comparison of performance between CE versus HPLC for biomarker analysis. Electrophoresis, 33(4), pp. 567-574. (doi: 10.1002/elps.201100415)

Bandin, F., Siwy, J., Breuil, B., Mischak, H., Bascands, J., Decramer, S. and Schanstra, J.P. (2012) Urinary proteome analysis at 5-year followup of patients with nonoperated ureteropelvic junction obstruction suggests ongoing kidney remodeling. Journal of Urology, 187(3), pp. 1006-1011. (doi: 10.1016/j.juro.2011.10.169)

Dawson, J. , Walters, M. , Delles, C. , Mischak, H. and Mullen, W. (2012) Urinary proteomics to support diagnosis of stroke. PLoS ONE, 7(5), e35879. (doi: 10.1371/journal.pone.0035879) (PMID:22615742) (PMCID:PMC3353991)

Kuznetsova, T., Mischak, H., Mullen, W. and Staessen, J.A. (2012) Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. European Heart Journal, 33(18), pp. 2342-2350. (doi: 10.1093/eurheartj/ehs185)

Rouse, R., Siwy, J., Mullen, W. , Mischak, H., Metzger, J. and Hanig, J. (2012) Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat. PLoS ONE, 7(4), e34606. (doi: 10.1371/journal.pone.0034606) (PMID:22509332) (PMCID:PMC3324487)

Siwy, J. et al. (2012) Evaluation of the zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS ONE, 7(12), e51334. (doi: 10.1371/journal.pone.0051334) (PMID:23236474) (PMCID:PMC3517416)

Albalat, A., Mischak, H. and Mullen, W. (2011) Urine proteomics in clinical applications: technologies, principal considerations and clinical implementation. Prilozi, 32(1), pp. 13-44.

Lankisch, T.O. et al. (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology, 53(3), pp. 875-884. (doi: 10.1002/hep.24103)

Lopez, L.M., Mullen, W. , Zürbig, P., Harris, S.E., Gow, A.J., Starr, J.M., Porteous, D.J., Mischak, H. and Deary, I.J. (2011) A pilot study of urinary peptides as biomarkers for intelligence in old age. Intelligence, 39(1), pp. 46-53. (doi: 10.1016/j.intell.2010.11.001)

Albalat, A., Mischak, H. and Mullen, W. (2011) Clinical application of urinary proteomics/peptidomics. Expert Review of Proteomics, 8(5), pp. 615-629. (doi: 10.1586/epr.11.46)

Carty, D.M. et al. (2011) Urinary proteomics for prediction of preeclampsia. Hypertension, 57(3), pp. 561-569. (doi: 10.1161/HYPERTENSIONAHA.110.164285)

Kistler, A.D. et al. (2011) A distinct urinary biomarker pattern characteristic of female fabry patients that mirrors response to enzyme replacement therapy. PLoS ONE, 6(6), e20534. (doi: 10.1371/journal.pone.0020534) (PMID:21698285) (PMCID:PMC3115947)

Metzger, J. et al. (2011) Diagnosis of subclinical and clinical acute T-cell-mediated rejection in renal transplant patients by urinary proteome analysis. Proteomics Clinical Applications, 5(5-6), pp. 322-333. (doi: 10.1002/prca.201000153)

Mischak, H., Thongboonkerd, V., Schanstra, J.P. and Vlahou, A. (2011) Renal and Urinary Proteomics. Proteomics Clinical Applications, 5(5-6), pp. 211-213. (doi: 10.1002/prca.201190031)

Mullen, W. , Delles, C. and Mischak, H. (2011) Urinary proteomics in the assessment of chronic kidney disease. Current Opinion in Nephrology and Hypertension, 20(6), pp. 654-661. (doi: 10.1097/MNH.0b013e32834b7ffa)

Mullen, W. , Gonzalez, J., Siwy, J., Franke, J., Sattar, N. , Mullan, A., Roberts, S., Delles, C. , Mischak, H. and Albalat, A. (2011) A pilot study on the effect of short-term consumption of a polyphenol rich drink on biomarkers of coronary artery disease defined by urinary proteomics. Journal of Agricultural and Food Chemistry, 59(24), pp. 12850-12857. (doi: 10.1021/jf203369r) (PMID:22070129)

Dakna, M., Harris, K., Kalousis, A., Carpentier, S., Kolch, W., Schanstra, J. P., Haubitz, M., Vlahou, A., Mischak, H. and Girolami, M. (2010) Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers. BMC Bioinformatics, 11(1), p. 594. (doi: 10.1186/1471-2105-11-594)

Good, D. M. et al. (2010) Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 9(11), pp. 2424-2437. (doi: 10.1074/mcp.M110.001917)

Mischak, H. et al. (2010) Recommendations for Biomarker Identification and Qualification in Clinical Proteomics. Science Translational Medicine, 2(46), 46ps42--. (doi: 10.1126/scitranslmed.3001249)

Alkhalaf, A. et al. (2010) Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE, 5(10), e13421. (doi: 10.1371/journal.pone.0013421) (PMID:20975990) (PMCID:PMC2958112)

Delles, C. et al. (2010) Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. Journal of Hypertension, 28(11), pp. 2316-2322. (doi: 10.1097/HJH.0b013e32833d81b7)

Maahs, D.M. et al. (2010) Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology. PLoS ONE, 5(9), e13051. (doi: 10.1371/journal.pone.0013051) (PMID:20927192) (PMCID:PMC2946909)

Metzger, J., Kirsch, T., Schiffer, E., Ulger, P., Mentes, E., Brand, K., Weissinger, E.M., Haubitz, M., Mischak, H. and Herget-Rosenthal, S. (2010) Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney International, 78(12), pp. 1252-1262. (doi: 10.1038/ki.2010.322)

Mischak, H., Delles, C. , Klein, J. and Schanstra, J.P. (2010) Urinary Proteomics Based on Capillary Electrophoresis-Coupled Mass Spectrometry in Kidney Disease: Discovery and Validation of Biomarkers, and Clinical Application. Advances in Chronic Kidney Disease, 17(6), pp. 493-506. (doi: 10.1053/j.ackd.2010.09.004)

Mischak, H. et al. (2010) Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clinical Applications, 4(4), pp. 464-478. (doi: 10.1002/prca.200900189)

Mischak, H. and Rossing, P. (2010) Proteomic biomarkers in diabetic nephropathy--reality or future promise? Nephrology Dialysis Transplantation, 25(9), pp. 2843-2845. (doi: 10.1093/ndt/gfq363)

Mischak, H. and Schanstra, J.P. (2010) CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clinical Applications, 5(1-2), pp. 9-23. (doi: 10.1002/prca.201000058)

Dakna, M., He, Z., Yu, W.C., Mischak, H. and Kolch, W. (2009) Technical, bioinformatical and statistical aspects of liquid chromatography–mass spectrometry (LC–MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: A critical assessment. Journal of Chromatography B, 877(13), pp. 1250-1258. (doi: 10.1016/j.jchromb.2008.10.048)

Harris, K., Girolami, M. and Mischak, H. (2009) Definition of valid proteomic biomarkers: a bayesian solution. Lecture Notes in Computer Science, 5780, pp. 137-149. (doi: 10.1007/978-3-642-04031-3_13)

Mischak, H., Coon, J., Novak, J., Weissinger, E., Schanstra, J. and Dominiczak, A. (2009) Capillary Electrophoresis-Mass Spectrometry As A Powerful Tool in Biomarker Discovery and Clinical Diagnosis: An Update of Recent Developments. Mass Spectrometry Reviews, 28(5), pp. 703-724. (doi: 10.1002/mas.20205)

zur Muhlen, C. et al. (2009) Evaluation of Urine Proteome Pattern Analysis for Its Potential To Reflect Coronary Artery Atherosclerosis in Symptomatic Patients. Journal of Proteome Research, 8(1), pp. 335-345. (doi: 10.1021/pr800615t)

Jantos-Siwy, J., Schiffer, E., Brand, K., Schumann, G., Rossing, K., Delles, C. , Mischak, H. and Metzger, J. (2008) Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. Journal of Proteome Research, 8(1), pp. 268-281. (doi: 10.1021/pr800401m) (PMID:19012428)

Jiang, H. et al. (2008) Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proceedings of the National Academy of Sciences of the United States of America, 105(32), pp. 11299-11304. (doi: 10.1073/pnas.0801457105)

Rossing, K., Mischak, H., Dakna, M., Zurbig, P., Novak, J., Julian, B. A., Good, D. M., Coon, J. J., Tarnow, L. and Rossing, P. (2008) Urinary Proteomics in Diabetes and CKD. Journal of the American Society of Nephrology, 19(7), pp. 1283-1290. (doi: 10.1681/ASN.2007091025)

Zimmerli, L.U. et al. (2008) Urinary proteomic biomarkers on coronary artery disease. Molecular and Cellular Proteomics, 7(2), pp. 290-298. (doi: 10.1074/mcp.M700394-MCP200)

Coon, J.J. et al. (2008) CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clinical Applications, 2(7-8), pp. 964-973. (doi: 10.1002/prca.200800024)

Book Sections

Albalat, A., Mullen, W. , Husi, H. and Mischak, H. (2017) Tissue proteomics in vascular disease. In: Touyz, R. M. and Schiffrin, E. L. (eds.) Hypertension: Methods and Protocols. Series: Methods in molecular biology (1527). Springer New York: New York, pp. 53-60. ISBN 9781493966233 (doi: 10.1007/978-1-4939-6625-7_4)

Book Reviews

Dhillon, A.S., Yip, Y.Y., Grindlay, G.J., Pakay, J.L., Dangers, M., Hillmann, M., Clark, W., Pitt, A.R., Mischak, H. and Kolch, W. (2009) The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cellular Signalling, 21(11), pp. 1645-1651. (doi: 10.1016/j.cellsig.2009.07.001)[Book Review]

Edited Books

Vlahou, A., Mischak, H., Zoidakis, J. and Magni, F. (Eds.) (2018) Integration of Omics Approaches and Systems Biology for Clinical Applications. Series: Wiley series on mass spectrometry. John Wiley & Sons, Inc: Hoboken, NJ. ISBN 9781119181149

Patents

Mischak, H. (2007) Method and device for the qualitative and/or quantitative analysis of a protein and/or peptide pattern of a liquid sample that is derived from the human or animal body. .